Foghorn Therapeutics
Clinical-stage biotechnology company developing precision therapies that modulate the chromatin regulatory system to correct abnormal gene expression. Uses an integrated discovery platform to identify genetically determined dependencies, generate and assay chromatin-related components at scale, advance small-molecule inhibitors and targeted protein degraders, and translate candidates through preclinical studies into early clinical trials.
Industries
Nr. of Employees
medium (51-250)
Foghorn Therapeutics
Patents
Products
Selective SMARCA2 (BRM) inhibitor — clinical candidate
Orally available, allosteric small-molecule inhibitor selective for the SMARCA2 ATPase versus its paralog SMARCA4; advanced into Phase 1 clinical evaluation for SMARCA4-mutant cancers (e.g., NSCLC).
Selective EP300 degrader — preclinical candidate
Targeted protein degrader directed at EP300 being advanced in preclinical studies for hematologic malignancies and prostate cancer with an IND targeted in 2027.
Selective CBP degrader — preclinical candidate
Targeted protein degrader aimed at CBP being developed for ER+ breast cancer indications.
Selective ARID1B degrader — preclinical candidate
Selective degrader targeting ARID1B for ARID1A-mutant cancers across multiple tumor types.
BRD9 degrader and other degrader programs
Development of BRD9-targeted degraders and additional degrader programs at preclinical stage, including formulations intended to modify dosing frequency.
FHT-77559
A potent selective CBP degrader molecule evaluated in murine xenograft models for tumor regression and pharmacokinetics.
Selective SMARCA2 (BRM) inhibitor — clinical candidate
Orally available, allosteric small-molecule inhibitor selective for the SMARCA2 ATPase versus its paralog SMARCA4; advanced into Phase 1 clinical evaluation for SMARCA4-mutant cancers (e.g., NSCLC).
Selective EP300 degrader — preclinical candidate
Targeted protein degrader directed at EP300 being advanced in preclinical studies for hematologic malignancies and prostate cancer with an IND targeted in 2027.
Selective CBP degrader — preclinical candidate
Targeted protein degrader aimed at CBP being developed for ER+ breast cancer indications.
Selective ARID1B degrader — preclinical candidate
Selective degrader targeting ARID1B for ARID1A-mutant cancers across multiple tumor types.
BRD9 degrader and other degrader programs
Development of BRD9-targeted degraders and additional degrader programs at preclinical stage, including formulations intended to modify dosing frequency.
FHT-77559
A potent selective CBP degrader molecule evaluated in murine xenograft models for tumor regression and pharmacokinetics.
Expertise Areas
- Chromatin biology and epigenetics
- Target identification and validation
- Targeted protein degradation
- Small-molecule drug discovery and medicinal chemistry
Key Technologies
- Targeted protein degradation (heterobifunctional degraders / PROTAC-like)
- Molecular glues and induced-proximity modalities
- Allosteric small-molecule ATPase inhibitors
- High-throughput screening (HTS) and robotic automation
News & Updates
Preprint reporting mechanistic studies of a BRG1/BRM inhibitor combined with decitabine in patients with advanced myeloid malignancies.
Clinical study results published in Clinical Cancer Research reporting safety, pharmacokinetics, and clinical activity of a dual BRG1/BRM inhibitor.
Clinical Cancer Research article describing a phase I trial of a BRD9 degrader in patients with synovial sarcoma or SMARCB1-loss tumors.
Preprint reporting mechanistic studies of a BRG1/BRM inhibitor combined with decitabine in patients with advanced myeloid malignancies.
Clinical study results published in Clinical Cancer Research reporting safety, pharmacokinetics, and clinical activity of a dual BRG1/BRM inhibitor.
Clinical Cancer Research article describing a phase I trial of a BRD9 degrader in patients with synovial sarcoma or SMARCB1-loss tumors.